Methods for treating non-cancerous disorders using hematopoietic cells
Inventors
Deitcher, Steven R. • Chen, Corinna X.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11273179-B2
Publication Date
2022-03-15
Expiration Date
Abstract
The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34+ cells and CD3+ cells. In certain embodiments, the compositions include CD34+ cells and facilitating cells. The methods are useful for treating blood cell disorders and other disorders that can be ameliorated by providing donor hematopoietic cells.
Core Innovation
The invention relates to methods of treating a non-cancerous disorder associated with aberrant activity of a hematopoietic cell. The method includes non-myeloablative conditioning, and the subject has not and will not receive a solid organ transplant, supporting a hematopoietic-focused treatment context.
A central feature is non-myeloablative conditioning comprising multiple rounds of total lymphoid irradiation. The invention pairs this conditioning with delivering a donor-derived cellular product composed of CD34+ cells and CD3+ cells.
The cellular product includes CD34+ cells and CD3+ cells at a specified dose range per kg of the subject’s weight. The described cellular product is structured using donor-derived hematopoietic cellular components intended to support stable mixed chimerism in recipients.
Claims Coverage
The document includes one independent claim that specifies treating a non-cancerous disorder with non-myeloablative conditioning including multiple rounds of total lymphoid irradiation, while excluding solid organ transplant recipients, followed by delivering a donor-derived cellular product containing CD34+ cells and CD3+ cells at a defined dose range. The independent claim contains two main inventive feature groups.
Non-myeloablative total lymphoid irradiation conditioning without solid organ transplant
A method of treating a non-cancerous disorder associated with aberrant activity of a hematopoietic cell by performing non-myeloablative conditioning comprising multiple rounds of total lymphoid irradiation, where the subject has not and will not receive a solid organ transplant.
Donor-derived CD34+ and CD3+ cellular product with defined CD3+ dose
Delivering to the subject a cellular product comprising CD34+ cells and CD3+ cells derived from a donor, wherein the cellular product comprises between about 1×10^8 and about 5×10^8 CD3+ cells/kg of the subject's weight.
Claim coverage centers on a treatment method combining non-myeloablative conditioning with multiple rounds of total lymphoid irradiation and delivery of a donor-derived cellular product containing CD34+ cells and CD3+ cells at a specified CD3+ dose range per kg.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?